T
Travecta Therapeutics
CNS drug delivery platform crossing blood-brain barrier
About Travecta Therapeutics
Travecta Therapeutics is a biopharmaceutical company that has developed a novel drug delivery platform, mVECTA™, to transport therapeutics across the blood-brain barrier (BBB) and blood-retinal barrier. The company's technology is built on the scientific discoveries of its founder, Dr. David Silver, a professor at Duke-NUS Medical School, who identified the MFSD2a transporter protein's natural mechanism for carrying lipids to the brain. This platform allows the company to conjugate existing or new small molecules to lipid scaffolds, enabling their transport into the central nervous system (CNS) to treat previously inaccessible targets.
The company was founded in 2017 by Dr. David Silver, Dr. Mahmood Ahmed, and the SPRIM Ventures team, including Michael Shleifer and Laurent Benissan. Dr. Silver's foundational research, published in 2014, revealed how the Mfsd2a protein transports essential fatty acids into the brain, a discovery that addresses a major challenge in medicine, as the BBB typically prevents about 98% of small-molecule drugs from entering. Travecta's business model focuses on leveraging this intellectual property, licensed from Duke-NUS, to create a proprietary pipeline of therapies and collaborate with large pharmaceutical companies. The company operates in the biopharmaceutical market, with offices in Singapore and Princeton, New Jersey, focusing on CNS disorders.
Travecta's lead product candidate, TVT-004, is a non-opioid drug targeting pain. The company's pipeline also includes programs in neuro-oncology, neuro-inflammation, neurodegeneration, anxiety, multiple sclerosis, and epilepsy. By making drugs permeable to the BBB, the mVECTA™ platform aims to repurpose ineffective drug candidates and develop new treatments for a wide range of neurological and ocular diseases. The company secured $27 million in an oversubscribed Series A funding round led by TKS1, a venture fund partnership between SPRIM and Tikehau Capital, to advance its pipeline, with plans to move its lead compound into clinical trials.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 51.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2020 | $15M | $60M | TKS1 | ↗ |
| SPINOUT✓Other financing | Jan 2017 | $0 | — | Duke-NUS Graduate Medical School Singapore | — |
Growth signals
Latest recorded traffic for Travecta Therapeutics is 220 monthly website visits. Travecta Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Travecta Therapeutics in the Philadelphia ecosystem
The Travecta Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- TKTKS1
Other known investors1 additional known investor
Duke-NUS Graduate Medical School Singapore
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Travecta Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Travecta Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









